



**CHANGE OF CONTENT OF PRICE INQUIRY NO. NUSI/79/PR69907/2024  
as of 29.07.2024.**

**Subject:** Project pn . "Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological safety" funded by the state budget from the Medical Research Agency, Pharmaceutical Plant Polpharma S.A.,  
Subject of purchase - **purchase and delivery of raw materials used in the synthesis of oligonucleotides.**

The ordering party informs that **on 05.08.2024 revised the content of the price inquiry** to the following extent:

Description before change	Description after the change
<b>IV. PRICE INQUIRY SUBJECT DELIVERY SITE AND DATE</b>	
<b>4.4 Delivery time for the subject of the price inquiry:</b>  <b>1.Part 1</b> Nitto Phase HL UnyLinker 300 – 50 g until 30.09.2024, 300 g until 20.12.2024 <b>2.Part 2</b> Cap A, (Acetonitrile/Acetic Anhydride, 80/20 v/v) – 2 l do until 30.08.2024, 12 l until 20.12.2024 <b>3.Part 3</b> Cap B, (Acetonitrile/N-methylimidazole/Pyridine, 50/20/30 v/v/v) – 2 l until 30.08.2024, 12 l until 20.12.2024 <b>4.Part 4</b> 1-Methylimidazole – 1 kg until 30.08.2024, 1 kg until 20.12.2024	<b>4.5 Delivery time for the subject of the price inquiry:</b>  <b>1.Part 1</b> Nitto Phase HL UnyLinker 300 – 50 g until 30.09.2024, 300 g until 20.12.2024 <b>2.Part 2</b> Cap A, (Acetonitrile/Acetic Anhydride, 80/20 v/v) – 2 l do until <b>30.09.2024</b> , 12 l until 20.12.2024 <b>3.Part 3</b> Cap B, (Acetonitrile/N-methylimidazole/Pyridine, 50/20/30 v/v/v) – 2 l until <b>30.09.2024</b> , 12 l until 20.12.2024 <b>4.Part 4</b> 1-Methylimidazole – 1 kg until <b>30.09.2024</b> , 1 kg until 20.12.2024
Description before change	Description after the change
<b>VIII. PLACE AND DEADLINE FOR SUBMISSION OF BIDS</b>	
<b>8.1</b> Bids shall be submitted by the deadline of <b>05/08/2024</b> electronically to: <a href="mailto:barbara.wendolowska@polpharma.com">barbara.wendolowska@polpharma.com</a> in the form of electronically signed documents or scans of documents.	<b>8.1</b> Bids shall be submitted by the deadline of <b>08/08/2024</b> electronically to: <a href="mailto:barbara.wendolowska@polpharma.com">barbara.wendolowska@polpharma.com</a> in the form of electronically signed documents or scans of documents.